The U.S. Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib), a RAS inhibitor for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Granted to Revolution Medicines, Inc. on August 26, 2026, the first-in-class approval provides a new targeted treatment option for a historically difficult-to-treat disease and was granted 6.5 months ahead of the user fee deadline.

Clinical Takeaway

Rasonque (daraxonrasib) is a once-daily oral RAS inhibitor approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. In a randomized trial of 500 previously treated patients, daraxonrasib improved median overall survival to 13.2 months versus 6.7 months with standard chemotherapy, establishing a new targeted treatment option in a disease with historically limited therapeutic choices.

Drug Profile & Mechanism

  • Brand name: Rasonque
  • Generic name: daraxonrasib
  • Drug class: RAS inhibitor
  • Mechanism: Targets multiple forms of RAS, a key driver of tumor growth in most patients with pancreatic adenocarcinoma
  • Route & schedule: Oral tablet, taken once daily
  • Manufacturer: Revolution Medicines, Inc.

Target Population

Rasonque is approved for adults with metastatic pancreatic adenocarcinoma who meet one of the following criteria:

  • Have received at least one prior systemic therapy, or
  • Are not candidates for multiagent systemic therapy

Disease context: Pancreatic adenocarcinoma accounts for approximately 90%–95% of the 67,000 new pancreatic cancer cases diagnosed annually in the United States, according to the National Cancer Institute. Despite representing roughly 3.2% of all cancer diagnoses, pancreatic adenocarcinoma accounts for a disproportionately high share of cancer deaths because of its typically late detection, aggressive disease course, and historically limited treatment options.

Study Design

  • Design: Randomized, open-label, multicenter clinical trial
  • Population: 500 adults with previously treated metastatic pancreatic adenocarcinoma
  • Comparator: Standard chemotherapy

Efficacy Outcomes

  • Overall Survival (OS):
    • Rasonque: Median OS of 13.2 months
    • Standard chemotherapy: Median OS of 6.7 months
    • Daraxonrasib nearly doubled median overall survival compared with standard chemotherapy

Safety

The most commonly reported adverse effects of Rasonque include:

  • Rash
  • Diarrhea
  • Stomatitis
  • Nausea
  • Fatigue
  • Vomiting
  • Abdominal pain
  • Edema
  • Decreased appetite
  • Hemorrhage

Regulatory Designations & Review Pathway

  • Breakthrough Therapy Designation: Granted by FDA
  • Orphan Drug Designation: Granted by FDA
  • Priority Review: Granted for this indication
  • Commissioner’s National Priority Voucher Pilot Program: Application reviewed under this program, which is intended to accelerate review of therapies addressing national public health priorities
  • Expanded Access: In May 2026, the FDA issued a “safe to proceed” letter allowing the sponsor to initiate an expanded access treatment protocol before approval
  • Approval timeline: Granted 6.5 months before the user fee deadline

Key Clinical Implications

✔ Rasonque (daraxonrasib) introduces a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are not candidates for multiagent systemic therapy.

✔ Daraxonrasib produced a substantial improvement in median overall survival—13.2 months versus 6.7 months with standard chemotherapy—in previously treated metastatic pancreatic adenocarcinoma.

✔ The approved indication includes patients who have received at least one prior systemic therapy as well as those who are not candidates for multiagent systemic therapy, extending the treatment option beyond the previously treated population studied in the randomized trial.

✔ Clinicians should counsel patients regarding the common adverse effects of daraxonrasib, including rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

Bottom Line

The FDA approval of Rasonque (daraxonrasib) introduces a first-in-class RAS-targeted treatment option for metastatic pancreatic adenocarcinoma. In previously treated patients, the once-daily oral therapy improved median overall survival to 13.2 months versus 6.7 months with standard chemotherapy. For oncology clinicians managing metastatic pancreatic adenocarcinoma, daraxonrasib adds a new targeted option for patients who have received prior systemic therapy or are not candidates for multiagent systemic therapy.

Sources: